NL8700366A - Combinatie van fu met bvdu als middel tegen adenocarcinoom. - Google Patents
Combinatie van fu met bvdu als middel tegen adenocarcinoom. Download PDFInfo
- Publication number
- NL8700366A NL8700366A NL8700366A NL8700366A NL8700366A NL 8700366 A NL8700366 A NL 8700366A NL 8700366 A NL8700366 A NL 8700366A NL 8700366 A NL8700366 A NL 8700366A NL 8700366 A NL8700366 A NL 8700366A
- Authority
- NL
- Netherlands
- Prior art keywords
- fluorouracil
- bvdu
- bromovinyl
- combination
- deoxyuridine
- Prior art date
Links
- 208000009956 adenocarcinoma Diseases 0.000 title claims abstract description 15
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 title claims description 29
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 12
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 10
- BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 231100000419 toxicity Toxicity 0.000 abstract description 7
- 230000001988 toxicity Effects 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000002243 precursor Substances 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8700366A NL8700366A (nl) | 1987-02-13 | 1987-02-13 | Combinatie van fu met bvdu als middel tegen adenocarcinoom. |
| JP63031681A JP2688057B2 (ja) | 1987-02-13 | 1988-02-10 | 抗腺がん剤 |
| US07/154,193 US4894365A (en) | 1987-02-13 | 1988-02-11 | Combinations of FU and BVU as anti-adenocarcinoma agents |
| DE8888200265T DE3862961D1 (de) | 1987-02-13 | 1988-02-12 | Mischungen von fu und bvu als adenokarzinomhemmende mittel. |
| EP88200265A EP0283065B1 (de) | 1987-02-13 | 1988-02-12 | Mischungen von FU und BVU als adenokarzinomhemmende Mittel |
| ES88200265T ES2032942T3 (es) | 1987-02-13 | 1988-02-12 | Un procedimiento para preparar un medicamento para uso contra adenocarcinomas. |
| AT88200265T ATE63817T1 (de) | 1987-02-13 | 1988-02-12 | Mischungen von fu und bvu als adenokarzinomhemmende mittel. |
| US07/373,824 US4988678A (en) | 1987-02-13 | 1989-06-29 | Combinations of FU and BVU as anti-adenocarcinoma agents |
| GR91401120T GR3002431T3 (en) | 1987-02-13 | 1991-08-02 | Combinations of fu and bvu as anti-adenocarcinoma agents |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8700366 | 1987-02-13 | ||
| NL8700366A NL8700366A (nl) | 1987-02-13 | 1987-02-13 | Combinatie van fu met bvdu als middel tegen adenocarcinoom. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8700366A true NL8700366A (nl) | 1988-09-01 |
Family
ID=19849574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8700366A NL8700366A (nl) | 1987-02-13 | 1987-02-13 | Combinatie van fu met bvdu als middel tegen adenocarcinoom. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US4894365A (de) |
| EP (1) | EP0283065B1 (de) |
| JP (1) | JP2688057B2 (de) |
| AT (1) | ATE63817T1 (de) |
| DE (1) | DE3862961D1 (de) |
| ES (1) | ES2032942T3 (de) |
| GR (1) | GR3002431T3 (de) |
| NL (1) | NL8700366A (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5137724A (en) * | 1990-05-23 | 1992-08-11 | Stichting Rega Vzw | Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines |
| PT806956E (pt) * | 1995-02-01 | 2003-01-31 | Resprotect Gmbh | Utilizacao de nucleosidos 5-substituidos para a inibicao de formacao de resistencia no tratamento com citostaticos |
| WO1999008110A1 (en) | 1997-08-08 | 1999-02-18 | Newbiotics, Inc. | Methods and compositions for overcoming resistance to biologic and chemotherapy |
| WO1999037753A1 (en) | 1998-01-23 | 1999-07-29 | Newbiotics, Inc. | Enzyme catalyzed therapeutic agents |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| MXPA02000762A (es) | 1999-07-22 | 2002-08-20 | Newbiotics Inc | Metodos para tratar tumores resistentes a terapia. |
| WO2001045690A2 (en) * | 1999-12-23 | 2001-06-28 | Newbiotics, Inc. | Use of bvdu for inhibiting the growth of hyperproliferative cells |
| DE10108851A1 (de) * | 2001-02-23 | 2002-09-12 | Resprotect Gmbh | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2016921B (en) * | 1978-03-27 | 1982-08-18 | Taiho Pharmaceutical Co Ltd | Anti cancer compositions containing uracil derivatives |
| IT1170232B (it) * | 1983-10-31 | 1987-06-03 | Anna Gioia Stendardi | Composizioni terapeutiche ad attivita' antivirale |
| EP0189755B1 (de) * | 1985-01-30 | 1990-01-03 | F. Hoffmann-La Roche Ag | Pharmazeutische Zusammensetzung |
-
1987
- 1987-02-13 NL NL8700366A patent/NL8700366A/nl not_active Application Discontinuation
-
1988
- 1988-02-10 JP JP63031681A patent/JP2688057B2/ja not_active Expired - Lifetime
- 1988-02-11 US US07/154,193 patent/US4894365A/en not_active Expired - Fee Related
- 1988-02-12 AT AT88200265T patent/ATE63817T1/de not_active IP Right Cessation
- 1988-02-12 ES ES88200265T patent/ES2032942T3/es not_active Expired - Lifetime
- 1988-02-12 EP EP88200265A patent/EP0283065B1/de not_active Expired - Lifetime
- 1988-02-12 DE DE8888200265T patent/DE3862961D1/de not_active Expired - Fee Related
-
1989
- 1989-06-29 US US07/373,824 patent/US4988678A/en not_active Expired - Fee Related
-
1991
- 1991-08-02 GR GR91401120T patent/GR3002431T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2688057B2 (ja) | 1997-12-08 |
| GR3002431T3 (en) | 1992-12-30 |
| ATE63817T1 (de) | 1991-06-15 |
| DE3862961D1 (de) | 1991-07-04 |
| EP0283065A1 (de) | 1988-09-21 |
| ES2032942T3 (es) | 1996-07-16 |
| EP0283065B1 (de) | 1991-05-29 |
| JPS63203619A (ja) | 1988-08-23 |
| US4988678A (en) | 1991-01-29 |
| US4894365A (en) | 1990-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10511689A (ja) | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法 | |
| JP2584947B2 (ja) | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療 | |
| WO1999051246A1 (en) | Antitumor agents | |
| EP0281380B1 (de) | Synergistische Wechselwirkung von Interleukin-2 und doppelsträngiger RNS | |
| NL8700366A (nl) | Combinatie van fu met bvdu als middel tegen adenocarcinoom. | |
| NL8301913A (nl) | Middel voor het versterken van de antitumor activiteit van een middel tegen tumoren. | |
| Eriguchi et al. | Pilot study for preoperative administration of 1-OHP to patients with advanced scirrhous type gastric cancer | |
| Kimura et al. | Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2′-tetrahydrofuryl)-5-fluorouracil | |
| JP2002515892A (ja) | サイトカインが関係する疾患治療法 | |
| Masaaki et al. | Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5′-deoxy-5-fluorouridine against adenocarcinoma 755 in mice: Correlation with pharmacokinetics of plasma 5-fluorouracil levels | |
| Vadlamudi et al. | Effect of combination treatment with 5-azacytidine and cytidine on the life-span and spleen and bone marrow cells of leukemic (L1210) and nonleukemic mice | |
| LV10574B (en) | The therapeutic use of low concentrations of trinitrobenzene, carminic acid and their derivatives as anti-cancer and anti-viral agents | |
| JPH0529365B2 (de) | ||
| US7671038B1 (en) | Method of therapeautic treatments including human immunodeficiency virus (HIV) disease and other conditions in a human host by administering adenine nucleotides | |
| JP6895435B2 (ja) | 細菌感染を治療する新規方法 | |
| Saijo et al. | Changes in serum erythropoietin levels during chemotherapy for lung cancer | |
| DE3007777C2 (de) | ||
| JPS6231690B2 (de) | ||
| JPH0145450B2 (de) | ||
| JPS6337767B2 (de) | ||
| JPH0332528B2 (de) | ||
| JPS6345372B2 (de) | ||
| JPS6223724B2 (de) | ||
| JPS621371B2 (de) | ||
| JPS6312845B2 (de) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| BV | The patent application has lapsed |